RENAL FLARE IN SLE PATIENTS
WITH IMPAIRED RENAL FUNCTION IN A RCT OF LJP 394
James A Tumlin, MD, et al.
Presented at the
36th Annual Meeting of the American Society of Nephrology
San Diego, CA
November 12-17, 2003
SAFETY
RESULTS FROM A RCT OF LJP 394 IN SLE PATIENTS WITH A HISTORY OF
RENAL DISEASE
Daniel J Wallace, MD, et al.
Presented at the
36th Annual Meeting of the American Society of Nephrology
San Diego, CA
November 12-17, 2003
EFFICACY RESULTS FROM
A RCT OF LJP 394 IN SLE PATIENTS WITH HISTORY OF RENAL DISEASE
James A Tumlin, MD, et al.
Presented at the
36th Annual Meeting of the American Society of Nephrology
San Diego, CA
November 12-17, 2003
REDUCTIONS IN ANTI-DSDNA
ANTIBODIES AND REDUCED RISK OF SLE RENAL FLARE AND MAJOR SLE FLARE
Matthew D Linnik, et al.
Presented at the
36th Annual Meeting of the American Society of
Nephrology
San Diego, CA
November 12-17, 2003
DOMAIN
SPECIFICITY OF AUTOANTIBODIES TO BETA2-GLYCOPROTEIN I IN PATIENTS
WITH ANTIPHOSPHOLIPID SYNDROME ENROLLED IN A PHASE 1/2 TRIAL WITH
LJP 1082
Matthew D. Linnik, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003
CLINICAL EFFICACY RESULTS
FROM A RCT OF LJP 394 IN SLE PATIENTS WITH HISTORY OF RENAL DISEASE
Mario H Cardiel, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003
SAFETY
RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (RCT) OF LJP 394 IN
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH A HISTORY OF
RENAL DISEASE
Daniel J Wallace, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003
SLE PATIENTS
WITH SUSTAINED REDUCTIONS IN ANTI-DSDNA ANTIBODIES HAVE A REDUCED
RISK OF RENAL FLARE AND MAJOR SLE FLARE
Matthew D Linnik, et al.
Presented at the
67th Annual Meeting of the American College
of Rheumatology
Orlando, FL
October 23-28, 2003
RESULTS
OF A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PHASE 1/2 CLINICAL
TRIAL (RCT) TO ASSESS THE SAFETY AND TOLERABILITY OF LJP 1082
IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
Arash Horizon, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003
SMALL
MOLECULE INHIBITORS OF SSAO AS THERAPEUTICS FOR INFLAMMATORY AND
AUTOIMMUNE DISORDERS
Luisa Salter-Cid, et al
Presented at
Inflammatory Processes in Drug Discovery
Philadelphia, PA
September 22-23, 2003
RANDOMIZED,
PLACEBO CONTROLLED, DOUBLE-BLIND PHASE III CLINICAL TRIAL FOR
THE EVALUATION OF LJP 394 (ABETIMUS SODIUM) IN THE TREATMENT OF
PATIENTS WITH SLE WHO ARE AT RISK FOR RENAL FLARE
Mario Cardiel for the LJP 394-90-09 Study Investigators Group
Presented at the
Annual European Congress of Rheumatology "EULAR 2003"
Lisbon, Portugal
June 18-21, 2003
|
IN
VIVO CHARACTERIZATION OF BIOCONJUGATE B CELL TOLERAGENS WITH SPECIFICITY
FOR AUTOANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME
Cockerill KA, et al.
Published in
International Immunopharmacology, 2003
Volume 3, Issue 12: pp 1667-1675
LJP
394 FOR THE PREVENTION OF RENAL FLARE IN PATIENTS WITH SYSTEMIC
LUPUS ERYTHEMATOSUS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED STUDY
Donato Alarcón-Segovia, et al.
Published in
Arthritis and Rheumatism, 2003
Volume 48, Issue 2: pp 442-454
IMPROVEMENT
IN HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS
PATIENTS ENROLLED IN A RANDOMIZED CLINICAL TRIAL COMPARING LJP 394
TREATMENT WITH PLACEBO
V. Strand, et al.
Published in
Lupus 2003
Volume 12: pp. 677-686
MULTIVALENT
POLY(ETHYLENE GLYCOL)-CONTAINING CONJUGATES FOR IN VIVO ANTIBODY
SUPPRESSION
Dave Jones, et al
Published in
Bioconjugate Chemistry, 2003
Volume 14, Issue 6: 1067-1076
|